A number of different research projects in academic, biotech, and pharmaceutical facilities, can be classified as genetic associations. These associations encompass the search for genes mediating disease, health, adverse events, or drug response. Identification of these variants can inform therapeutic strategies, identify drug targets, or accelerate approval of pharmaceutical compounds by either avoiding adverse events or highlighting subjects most likely to benefit from the administration of a compound. Cypher Genomics provides the computational tools and infrastructure to perform a modern whole genome association study.
The majority of genetic variants that influence disease risk and/or adverse drug response are thought to be heterogeneous and rare. For this reason, straightforward statistical tests are unlikely to identify variants of interest in modern genetic research studies. Cypher Genomics provides the tools and expertise to bring modern genetic investigation to any institute.
Cypher Annotations, which encompass nearly all of our Technology products, are applied to the genomes under investigation. These annotated genomes are then driven through Cypher Analytics in order to identify groups of variants or genes that underlie the phenotype of interest.
Cypher Analytics relies upon all pieces of the Cypher Genomics technology portfolio to produce prioritized and biologically connected variant sets, which are then passed through state-of-the-art statistical tools for rare variant association. Our end-to-end approach brings decades of computational and biostatistics expertise to any operation.
Learn more about these methods in Technology.
Explore our solutions: